Search results for "SYMPTOMATIC ASTHMA"

showing 1 items of 1 documents

Efficacy of once-daily tiotropium Respimat in adults with asthma at GINA Steps 2-5.

2020

Tiotropium Respimat is an efficacious add-on to maintenance treatment in patients with symptomatic asthma. Currently, the Global Initiative for Asthma (GINA) strategy recommends tiotropium for patients at Steps 4–5. To assess the clinical benefits of tiotropium Respimat across asthma severities, GINA Steps 2–5, a post hoc analysis of five double-blind trials (12–48-weeks; patients aged 18–75 years) investigated the effect of tiotropium Respimat, 5 μg or 2.5 μg, versus placebo, on peak forced expiratory volume in 1 s (FEV1) within 3 h post-dose (FEV1(0–3h)) response, and Asthma Control Questionnaire-7 (ACQ-7) responder rate. GINA step grouping was based on patients’ background treatment regi…

Pulmonary and Respiratory MedicineAdultMalemedicine.medical_specialtyRespimatAdolescentINHALED CORTICOSTEROIDSPlaceboSALMETEROLDouble-Blind MethodADD-ONStatistical significanceInternal medicineAsthma controlPost-hoc analysisAdministration InhalationmedicineHumansPharmacology (medical)Tiotropium BromideCOMBINATIONDisease severityLungAsthmaAgedbusiness.industryTiotropiumBiochemistry (medical)IMPROVES LUNG-FUNCTIONOdds ratioMiddle Agedmedicine.diseaseGINAConfidence intervalLung functionAsthmarespiratory tract diseasesBronchodilator AgentsTreatment OutcomeSAFETYFemaleSalmeterolbusinessmedicine.drugSYMPTOMATIC ASTHMAPulmonary pharmacologytherapeutics
researchProduct